[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610770":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":24,"interventions":37,"overallOfficials":13,"centralContacts":46,"locations":52,"responsibleParty":66,"collaborators":13,"id":70,"slug":13,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":13,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":13,"enrollmentInfo":77,"targetDuration":13,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":89,"whyStopped":13,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Assaf-Harofeh Medical Center","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Blood pressure","Prevention of intra dialytic hypertension","1 month",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"TRIPLE",[21,22,23],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[25,31],{"label":26,"type":27,"description":28,"interventionNames":29},"Sodium bicarbonate","EXPERIMENTAL","PO Sodium bicarbonate 500mg X2\u002Fday",[30],"Drug: Sodium Bicarbonate (NaHCO3)",{"label":32,"type":33,"description":34,"interventionNames":35},"Placebo","PLACEBO_COMPARATOR","1 tab X2\u002Fday",[36],"Drug: Placebo",[38,43],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":13},"DRUG","Sodium Bicarbonate (NaHCO3)","Prescribing Sodium Bicaronate for intra-dualytic hypertension",[26],{"type":39,"name":32,"description":44,"armGroupLabels":45,"otherNames":13},"1 tab X 2\u002Fday",[32],[47],{"name":48,"role":49,"phone":50,"phoneExt":13,"email":51},"Shani Zilberman Itskovich, Dr.","CONTACT","+97289779383","shani.zilberman@mail.huji.ac.il",[53],{"facility":54,"status":13,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":13},"Shamir medical center","Ẕerifin","Is","70300","Israel","IL",{"type":61,"coordinates":62},"Point",[63,64],34.84852,31.95731,{"lat":64,"lon":63},{"type":67,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Shani Zilberman Itskovich","Dr.","100610770",false,"NCT07231900","Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients","Inclusion Criteria:\n\n* Chronic hemodialysis patient \\> 3 months\n* 3 dialysis per week, KTV\\>1.2\n* capable of informed concent.\n* rise in blood pressure during hemodialysis \\> 10 mm Hg, for at least 50% of dialysis sessions in the month prior to inclusion.\n* Normal volume status, by clinical physician assessment + bioimpedance\n\nExclusion Criteria:\n\n* age under 18,\n* pregnancy\n* unable to sign informed concent\n* planned for kidney transplant in the following 3 month.\n* congestive heart failure (NYHA 3-4)\n* hospitalization for acute MI or CHF in the past 3 months.\n* low compliece to medical therapy\n* regular pre-dialysis tests with bicarbonate \\> 24 in the past 3 months","ALL","18 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82,83],"PHASE2","PHASE3","The study is designed to diminish intra-dialytic hypertension in chrnic hemodialysis patients suffering from metabolic acidosis (low bicarbonate levels). The intervention is a tab of 500 mg sodium bicarbonate twice a day for one month, vs. placebo.",[86],"Hypertension in Dialysis Patients",[88],"Intra-dialytic hypertension","NOT_YET_RECRUITING","2025-11-14",{"date":92,"type":93},"2025-11-17","ACTUAL",{"date":95,"type":79},"2025-11-10",{"date":97,"type":79},"2027-12-01",{"name":5,"class":6},1]